Results 171 to 180 of about 48,562 (198)

Selective inhibitors of the Janus kinase Jak3—Are they effective?

Bioorganic & Medicinal Chemistry Letters, 2014
Jak3, together with Jak1, is involved in signal transduction initiated by cytokines signaling through the common gamma chain which are important in immune homeostasis and immune pathologies. Based on genetic evidence Jak3 has been considered to be an attractive target for immunosuppression.
Gebhard, Thoma, Peter, Drückes, Hans-Günter, Zerwes   +2 more
openaire   +2 more sources

Thromboembolism and Janus Kinase Inhibitors

Drug Safety, 2020
Fowzia Ibrahim, David L. Scott
openaire   +3 more sources

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Advances in Janus Kinase Inhibitors for Vitiligo Treatment

Drug Research
Abstract Vitiligo is a cutaneous autoimmune disease characterized by the destruction of epidermal melanocytes leading to white patches with a global prevalence of about 0.5–2%, and patients’ quality of life are greatly affected by the change in appearance and social ...
Yue Liao, Wanlin Wang, Ruizhi Zhang, Jijun Huang, Jiamin Liu, Xiaokang Shan, Xiaojing Gao, Jin Bu, Yaping Tang, Erxia Shen   +9 more
openaire   +2 more sources

AN OVERVIEW OF JANUS KINASE INHIBITORS

Rheumatology Quarterly
With a better understanding of the pathogenesis of inflammatory rheumatic diseases, different treatments pathways have emerged. In recent years, Janus kinase inhibitors (JAKinibs) have become one of these treatment pathways. It has come into clinical use as an effective treatment agent, especially in rheumatoid arthritis and spondyloarthropathy. In the
openaire   +1 more source

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

Journal of Inflammation Research, 2023
Rongxiu Huo, Xinxiang Huang, Jinying Lin   +2 more
exaly  

Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

Journal of Dermatological Treatment, 2022
Kevin Phan, Steven Phan, Stephen Shumack   +2 more
exaly  

Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis

Therapeutic Advances in Musculoskeletal Disease, 2021
Chenghua Weng, Leixi Xue, Wentian Lu
exaly  

Janus Kinase (JAK) Inhibitors

2022
Courtney E. Heron, Lindsay C. Strowd, Steven R. Feldman   +2 more
openaire   +1 more source

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Journal of Cellular Physiology, 2020
Arezoo Hosseini, Tohid Gharibi, Faroogh Marofi   +2 more
exaly